Navigation Links
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Date:8/26/2007

rus infection," said Dr. Ann-Lii Cheng, principal investigator and professor of medicine, National Taiwan University Hospital. "These study results confirm that Nexavar's efficacy and tolerability in liver cancer extends across ethnic groups and geographies and suggest that Nexavar could meet a tremendous unmet need for patients and families impacted by this devastating disease."

HCC, the most common form of liver cancer, is responsible for about 90 percent of the primary malignant liver tumors in adults.(1,2) Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths globally.(3) Over 600,000 cases of liver cancer are diagnosed globally each year.(3) In 2002, approximately 600,000 people died of liver cancer including approximately 360,000 in China, Korea and Japan, 57,000 in Europe and 13,000 in the United States.(4) Risk factors for liver cancer include ongoing (chronic) infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV).(5)

About the Asia-Pacific Liver Cancer Study

This double-blind, randomized, placebo-controlled Phase 3 trial was designed to evaluate Nexavar in patients with advanced HCC, or primary liver cancer, who had no prior systemic therapy. The study enrolled 226 patients from sites in China, Korea and Taiwan. The primary objectives of the study were to compare overall survival, time to progression (TTP) and progression free survival (PFS) in patients administered Nexavar 400 mg twice daily versus patients administered placebo.

Nexavar's Differentiated Mechanism

Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) -- two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET. Preclinical mod
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.; Onyx
Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
2. Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007
3. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
4. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
5. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
7. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
8. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
9. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
10. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
11. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)...  Regulatory leaders in the pharmaceutical industry continue to ... "21 st Century Cures." This ... by Congress soon and if enacted into law, it ... developed and marketed in the United States ... to consider how the proposed changes could impact their ...
(Date:4/17/2015)... 17, 2015 Nonin Medical, a global leader ... Chief Operating Officer Steve Bucholz will retire ... expanding his role as Chief Executive Officer. In addition, ... Technology Officer. Operations will transition to David Noel ... has been instrumental to Nonin Medical,s growth," Mr. ...
(Date:4/17/2015)... DUBLIN , Apr. 17, 2015 Research and ... addition of the "Medical Equipment Rental and Leasing ... offering. This report analyzes the worldwide markets ... The report provides separate comprehensive analytics for the US, ... , and Rest of World. Annual estimates ...
Breaking Medicine Technology:21st Century Cures: A Regulatory Game-Changer for the Pharmaceutical Industry 2Nonin Medical's Philip Isaacson Expands CEO Role; President and COO Steve Bucholz to Retire May 1 2Medical Equipment Rental and Leasing Market 2015-2020 - Global Strategic Business Report - Healthcare Spending Slowdown Bodes Well for Medical Equipment Leasing 2
... WELLESLEY HILLS, Mass., Aug. 25 Joseph F. ... Spherics, Inc. ("Spherics") for,the benefit of creditors, announced ... at a sealed bid auction on October 10,2008., ... Levodopa-Carbidopa that,is the current gold standard treatment for ...
... Development Studies ... Planned, COPENHAGEN, ... ofatumumab in chronic lymphocytic,leukemia and non-Hodgkin,s lymphoma., Genmab A/S (OMX: GEN) ... (CLL) and follicular,non-Hodgkin,s lymphoma (NHL) this year., "Genmab and GSK have ...
Cached Medicine Technology:Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels 2Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4
(Date:4/19/2015)... (PRWEB) April 19, 2015 Family and friends ... for Brains in Memory of Brad Baddeley event to ... Aneurysm Foundation. , Bowling for Brains is cheduled to take ... 4700 Dudley Street in Lincoln, Nebraska. Participants may arrive at ... to 3:00pm. , The cost is only $4 per game ...
(Date:4/18/2015)... has released a new blog post explaining that ... a car accident. , Car insurance policies can ... can pay for car repairs and even medical expenses ... coverage when they are driving. , An ... riders that offer extra coverage options. One of the ...
(Date:4/18/2015)... 18, 2015 Review of Ophthalmology magazine ... ‘Strategies for Success’ program for cataract surgeons attending the ... San Diego, where eye surgeon Jeffrey L. Martin, MD ... event. Dr. Martin is the Managing Partner of North ... chose Dr. Martin to lead this year’s discussion on ...
(Date:4/18/2015)... York (PRWEB) April 18, 2015 Thousand ... filed on behalf of individuals who were allegedly harmed ... continue to move forward in the U.S. District Court, ... April 10th, the Court has amended an earlier Case ... cases. Among other things, the new amendment permits the ...
(Date:4/18/2015)... “ ArcAngel ” was featured on NewsWatch as part ... latest and coolest applications on the market for ... and technology expert, conducted the app review and shared with ... In a turbulent world, people may find themselves in dangerous ... their first move, but some situations can be avoided if ...
Breaking Medicine News(10 mins):Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 2Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 3Health News:Auto Insurance Plans Can Cover Physical Injuries Caused By An Accident! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:A Personal Safety Application was Featured on NewsWatch Television 2
... vaccine to,prevent shingles was approved for use in 2006, ... age 60 and older who,previously had chickenpox. But two ... primarily affects adults with weakened immune,systems -- have left ... This uncertainty prompted a group of researchers led by,Barbara ...
... SWEDESBORO, N.J., Dec. 12 Yesterday, the U.S. ... vacated the Drug Enforcement,Administration,s (DEA) 2006 revocation of ... been challenging the DEA,s,decision since it first was ... company,s appeal of the,DEA,s decision and the DEA,s ...
... of trouble was 2 to 4 times greater than with ... -- Infants delivered by elective Caesarean section are up to ... born vaginally or by emergency C-section, says a Danish study ... British Medical Journal . , Researchers analyzed data on 34,000 ...
... (Dec. 12, 2007) -- Weill Cornell Medical College has ... & Melinda Gates Foundation to help fight tuberculosis, an ... kills nearly two million yearly -- mostly in the ... developing innovative TB drugs that are more effective than ...
... Officials Will Explain Regulatory Plans for Cutting-Edge,Technology at National ... 12 Nanotechnology was,incorporated into more than $50 billion ... 2014, the market will grow to $2.6 trillion.,By 2011, ... be,sold -- up from more than $3 billion in ...
... Dec. 12 Research that delivers,winning practices for improving ... management - is now available in the Best,Practice Database, ... Best Practices, LLC., To review sample key findings ... page with links to each study at this address:, ...
Cached Medicine News:Health News:Mayo Clinic Proceedings Article Offers New Data About the Impact of the Shingles Virus on Healthy Adults 2Health News:Mayo Clinic Proceedings Article Offers New Data About the Impact of the Shingles Virus on Healthy Adults 3Health News:Wedgewood Pharmacy: U.S. Court of Appeals Vacates DEA Action 2Health News:Wedgewood Pharmacy: U.S. Court of Appeals Vacates DEA Action 3Health News:Wedgewood Pharmacy: U.S. Court of Appeals Vacates DEA Action 4Health News:Elective Caesareans Raise Risk of Breathing Problems in Newborns 2Health News:Weill Cornell receives $2.4 million in grants from Gates Foundation to fight tuberculosis 2Health News:Weill Cornell receives $2.4 million in grants from Gates Foundation to fight tuberculosis 3Health News:Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation and Policy 2Health News:Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation and Policy 3Health News:Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation and Policy 4Health News:Best Practice Database Adds New Research on Contract Management and New Product Development 2
The design of this table top is based on advanced functionality for specific urological requirements. This composite product sets a new standard for urological imaging....
... The Hydra Vision® Plus DR Urology System ... It is the first dedicated digital urology ... the DR was designed to use optimized ... (16") image intensifier for maximum anatomical coverage ...
... KCIs AirMaxxis™ is a pressure relief mattress overlay ... air loss therapy for those patient with skin ... ,INDICATIONS: , Patients whose body weight and ... issue to the patient or staff during the ...
... A Bariatric bed providing a flexible ... pressure relief mattress system for comfort, support, ... weighing up to 850 lbs. ,Large patients ... patient using a static mattress that would ...
Medicine Products: